Gosselies, Belgium - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, announces that it has received a transparency notification from S.R.I.W. SA (Societe Regionale d'Investissement de Wallonie) dated 14 December 2021. The transparency notification indicates that the shareholdings held by its subsidiary, Sofipole SA (Societe Wallonne pour le Financement des Infrastructures des Poles de Competitivite), have passively crossed below the threshold of 5% as a result of the issuance of new shares of Bone Therapeutics via the private placement on 2 December 2021. The new shares were delivered to the participating investors on 7 December 2021.
The notification dated 14 December 2021 contains the following information:
Reason for the notification: Passive crossing of a threshold
Notification by: A parent undertaking or a controlling person
Persons subject to the notification requirement: S.R.I.W. SA & Sofipole SA
Transaction date: 7 December 2021
Threshold that is crossed: 5%
Denominator: 21,310,520
Notified details:
Full chain of controlled undertakings through which the holding is effectively held: The Walloon Region holds 99.43% of S.R.I.W. SA which controls 60% of the shares of Sofipole SA.
Additional information: This declaration has been issued as SOFIPOLE SA has crossed below the 5% threshold.
The notification can be consulted on the website of Bone Therapeutics, under the heading 'Shareholder Information'.
About Bone Therapeutics
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a diversified portfolio of cell therapies at different stages ranging from pre-clinical programs in immunomodulation to mid stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.
Bone Therapeutics' core technology is based on its cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics' scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company has initiated patient recruitment for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.
Bone Therapeutics' cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at www.bonetherapeutics.com.
Contact:
Bone Therapeutics SA
Miguel Forte, MD, PhD
Chief Executive Officer
Lieve Creten
Chief Financial Officer ad interim
Tel: +32 (0) 71 12 10 00
E: investorrelations@bonetherapeutics.com
Belgian Media and Investor
Bepublic
Bert Bouserie
Tel: +32 (0)488 40 44 77
E: bert.bouserie@bepublicgroup.be
International Media
Image Box Communications
Neil Hunter
E: neil.hunter@ibcomms.agency
Michelle Boxall
Tel: +44 (0)20 8943 4685
E: michelle@ibcomms.agency
French Media and Investor
NewCap Investor Relations & Financial Communications
Pierre Laurent
Louis-Victor Delouvrier
Arthur Rouille
Tel: +33 (0)1 44 71 94 94
E: bone@newcap.eu
BIOSENIC SA 
